Brief: Xlife Sciences AG Says Transaction With Veraxa, Offers Potential For A Significant Partial Exit Of Company's Investment
25/04/2025 06:06
April 25 (Reuters) - Xlife Sciences AG XLS.S: XLIFE SCIENCES AG PUBLISHES 2024 ANNUAL REPORT: STRATEGIC EXPANSION, TECHNOLOGICAL MILESTONES, AND INTERNATIONAL CAPITAL MARKET PRESENCE XLIFE SCIENCES AG - PLANS DUAL LISTING ON SIX AND LSE XLIFE SCIENCES AG - TRANSACTION WITH VERAXA, OFFERS POTENTIAL FOR A SIGNIFICANT PARTIAL EXIT OF COMPANY'S INVESTMENT Source text: ID:nEQ66tKP3a Further company coverage: XLS.S ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xlife Sciences AG
See all newsSwiss stocks - Factors to watch on July 17
Brief: Xlife Sciences AG Says Transaction With Veraxa, Offers Potential For A Significant Partial Exit Of Company's Investment
Veraxa Biotech to merge with SPAC Voyager in $1.64 billion deal (updated)
Veraxa Biotech to merge with SPAC Voyager in $1.64 billion deal
Brief: Xlife Sciences AG Says Veraxa Biotech AG To Merge With Voyager Acquisition Corp.